SUBSCRIBE
SUBSCRIBE

Phase 3

So Long 2016 (and Good Riddance?)
Drug Development
BioPharm Executive: So Long 2016 (and Good Riddance?)
December 7, 2016
 · 
8 min read
Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases
Drug Development
Celgene Decides to Not Move Forward With Phase III Portion of tnAcity
December 7, 2016
 · 
2 min read
Top 5 Best U.S. Cities for Pharma and Biotech Scientist Jobs
Drug Development
4 Massachusetts Biotechs Making Waves at American Society of Hematology
December 6, 2016
 · 
2 min read
Antares Pharma Implodes After FDA Responds to Its Xyosted NDA
Drug Development
Top 7 Jaw-Dropping Pipeline Blowups This Year
December 5, 2016
 · 
4 min read
Novartis to Hold On to Its 33% Stake in Roche—For Now
Drug Development
Novartis AG’ CAR-T Drug Sends 82% of Patients’ Blood Cancer into Remission, Eyes 2017 for Marketing
December 5, 2016
 · 
2 min read
Proteostasis and Roche Diagnostics Ink Huge Space in New Boston Hub
Drug Development
bluebird bio, Celgene’s Multiple Myeloma CAR-T Drug Shines in Tiny Study
December 1, 2016
 · 
2 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Drug Development
Juno Halts CAR-T Trial for Second Time Following Additional Patient Deaths
November 23, 2016
 · 
2 min read
Devastation Hits as Eli Lilly's Alzheimer's Drug Flunks Late-Stage Study, Shares Tank
Drug Development
Devastation Hits as Eli Lilly’s Alzheimer’s Drug Flunks Late-Stage Study, Shares Tank
November 23, 2016
 · 
2 min read
Proteostasis and Roche Diagnostics Ink Huge Space in New Boston Hub
Drug Development
5 Drug Giants That Could Dominate the $13 Billion Alzheimer’s Market
November 22, 2016
 · 
3 min read
Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases
Drug Development
The Franchise That Could Bring in Another $20 Billion for Celgene
November 22, 2016
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
February 3, 2026
 · 
9 min read
Press Releases
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients
February 3, 2026
 · 
12 min read
Press Releases
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
February 3, 2026
 · 
6 min read
Press Releases
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites
February 2, 2026
 · 
2 min read
Press Releases
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
February 2, 2026
 · 
4 min read
Press Releases
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
February 2, 2026
 · 
8 min read
Press Releases
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
February 2, 2026
 · 
14 min read
Press Releases
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
February 2, 2026
 · 
11 min read
Press Releases
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
February 1, 2026
 · 
12 min read
Press Releases
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
February 1, 2026
 · 
12 min read
Press Releases
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
January 30, 2026
 · 
9 min read
Press Releases
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
January 30, 2026
 · 
6 min read
Press Releases
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
January 29, 2026
 · 
7 min read
Press Releases
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
January 29, 2026
 · 
3 min read
Press Releases
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
January 29, 2026
 · 
2 min read
Press Releases
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
January 29, 2026
 · 
8 min read
Press Releases
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
January 29, 2026
 · 
6 min read
Press Releases
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
January 29, 2026
 · 
4 min read
Press Releases
OKYO Pharma Announces Successful Type C Meeting with the FDA
January 29, 2026
 · 
5 min read
Press Releases
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
January 28, 2026
 · 
3 min read
Load More